Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/18274
Title: Genome-wide association study: Exploring the genetic basis for responsiveness to ketogenic dietary therapies for drug-resistant epilepsy.
Authors: Schoeler, Natasha E;Leu, Costin;Balestrini, Simona;Mudge, Jonathan M;Steward, Charles A;Frankish, Adam;Leung, Mary-Anne;Mackay, Mark;Scheffer, Ingrid;Williams, Ruth;Sander, Josemir W;Cross, J Helen;Sisodiya, Sanjay M
Affiliation: Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK
UCL Great Ormond Street Institute of Child Health, London, UK
NIHR University College London Hospitals Biomedical Research Centre, UCL Institute of Neurology, London, UK
Chalfont Centre for Epilepsy, Chalfont St Peter, UK
European Molecular Biology Laboratory, Wellcome Genome Campus, European Bioinformatics Institute, Cambridge, UK
Wellcome Genome Campus, Congenica Ltd, Cambridge, UK
Children's Neurosciences Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK
Department of Paediatrics, The University of Melbourne, Royal Children's Hospital, Melbourne, Vic., Australia
Murdoch Children's Research Institute, Melbourne, Vic., Australia
Epilepsy Research Centre, Department of Medicine, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australia
The Florey Institute of Neuroscience and Mental Health, Austin Health, Heidelberg, Victoria, Australia
Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede, The Netherlands
Great Ormond Street Institute of Child Health, London, UK
Young Epilepsy, Lingfield, UK
Issue Date: Aug-2018
EDate: 2018-07-16
Citation: Epilepsia 2018; 59(8): 1557-1566
Abstract: With the exception of specific metabolic disorders, predictors of response to ketogenic dietary therapies (KDTs) are unknown. We aimed to determine whether common variation across the genome influences the response to KDT for epilepsy. We genotyped individuals who were negative for glucose transporter type 1 deficiency syndrome or other metabolic disorders, who received KDT for epilepsy. Genotyping was performed with the Infinium HumanOmniExpressExome Beadchip. Hospital records were used to obtain demographic and clinical data. KDT response (≥50% seizure reduction) at 3-month follow-up was used to dissect out nonresponders and responders. We then performed a genome-wide association study (GWAS) in nonresponders vs responders, using a linear mixed model and correcting for population stratification. Variants with minor allele frequency <0.05 and those that did not pass quality control filtering were excluded. After quality control filtering, the GWAS of 112 nonresponders vs 123 responders revealed an association locus at 6p25.1, 61 kb upstream of CDYL (rs12204701, P = 3.83 × 10-8 , odds ratio [A] = 13.5, 95% confidence interval [CI] 4.07-44.8). Although analysis of regional linkage disequilibrium around rs12204701 did not strengthen the likelihood of CDYL being the candidate gene, additional bioinformatic analyses suggest it is the most likely candidate. CDYL deficiency has been shown to disrupt neuronal migration and to influence susceptibility to epilepsy in mice. Further exploration with a larger replication cohort is warranted to clarify whether CDYL is the causal gene underlying the association signal.
URI: http://ahro.austin.org.au/austinjspui/handle/1/18274
DOI: 10.1111/epi.14516
ORCID: 0000-0001-6202-1497
0000-0001-6041-9661
0000-0002-2311-2174
PubMed URL: 30009487
Type: Journal Article
Subjects: CDYL
biomarker
genetics
high-fat
low-carbohydrate
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.